Patent · US Expired

Soluble CTLA4 mutant molecules and uses thereof

US7105166B1 · kind B1 · utility

21Cited by
16References
12Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 3, 2000
Grant dateSep 12, 2006
Priority date
Expiry dateApr 10, 2022

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides soluble CTLA4 mutant molecules which bind CD80 and/or CD86 antigen.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.